Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azstarys in children with ADHD
NCT06359899Phase 3Completed
- Sponsor
- Ark Biosciences
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of serdexmethylphenidate + dexmethylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Ark Biosciences. Started May 2024; status: completed.
02
Drugs
serdexmethylphenidate + dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06359899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359899.